Dianthus Therapeutics (DNTH) Long-Term Investments (2024 - 2025)
Dianthus Therapeutics (DNTH) recorded quarterly Long-Term Investments of $110.1 million in Q4 2025, down 27.96% quarter-over-quarter from $152.9 million in Q3 2025, and up 34.76% on a YoY basis from $81.7 million in Q4 2024.
Dianthus Therapeutics (DNTH) Long-Term Investments (2024 - 2025) Analysis & Trends
Dianthus Therapeutics' Long-Term Investments history runs 2 years deep, the most recent figure standing at $110.1 million for Q4 2025.
- In Q4 2025, Long-Term Investments rose 34.76% year-over-year to $110.1 million; the TTM figure through Dec 2025 stood at $110.1 million (up 34.76% YoY), while the FY2025 annual figure was $110.1 million, up 34.76% from the prior year.
- Long-Term Investments was $110.1 million for Q4 2025 at Dianthus Therapeutics, down from $152.9 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $152.9 million in Q3 2025 to a low of $51.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Dianthus Therapeutics | 3.60 Bn | 3.19 Bn | - | 110.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 110.14 Mn |
| Sep 30, 2025 | 152.87 Mn |
| Jun 30, 2025 | 51.71 Mn |
| Mar 31, 2025 | 68.31 Mn |
| Dec 31, 2024 | 81.73 Mn |
| Sep 30, 2024 | 61.48 Mn |